KRAS G12D

Ask MedXY AI

Latest news

Tag

Gastroenterologyimmune suppressionKRAS G12D

Targeting Oncomucin-Driven Immunosuppression Improves KRAS G12D Inhibition in Pancreatic Cancer

By MedXY|May 28, 2026

Oncomucins such as MUC4 and MUC16 help pancreatic cancer evade immunity through EGFR/UNC5B signaling. Targeting these mucins may enhance KRAS G12D inhibitor efficacy and reduce tumor burden.

newsKRAS G12DPancreatic Cancer

Oral KRAS G12D inhibitor GFH375 produces ORR 40.7% and DCR 96.7% in previously treated KRAS G12D pancreatic ductal adenocarcinoma: Key readouts from ESMO 2025

By MedXY|Nov 24, 2025

A global phase I/II study of oral GFH375 in previously treated KRAS G12D mutant PDAC showed a 40.7% ORR, 96.7% DCR, median PFS 5.52 months, and manageable toxicity, supporting ongoing phase III evaluation.